Allogene Therapeutics Inc is the United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.
| Website: | www.allogene.com |
| Email: | IR@allogene.com |
| Main Phone: | +1 650 457-2700 |
| Address: | 210 East Grand Avenue |
| State: | CA |
| City / Town: | South San Francisco |
| Country: | USA |
| Postal Code: | 94080 |
| Exchange: | NGS |
| CEO: | David D. Chang |
| Employees: | 190 |
| NAICS: | Biological Product (except Diagnostic) Manufacturing(325414) |
80 deals created $44.8 billion of market value for newly public US biotechs (Image: Genomics Law Report).
ALPN-202 combines dual checkpoint blockade action with T-cell costimulation
Allogene Therapeutics Inc is the United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.
| Website: | www.allogene.com |
| Email: | IR@allogene.com |
| Main Phone: | +1 650 457-2700 |
| Address: | 210 East Grand Avenue |
| State: | CA |
| City / Town: | South San Francisco |
| Country: | USA |
| Postal Code: | 94080 |
| Exchange: | NGS |
| CEO: | David D. Chang |
| Employees: | 190 |
| NAICS: | Biological Product (except Diagnostic) Manufacturing(325414) |
80 deals created $44.8 billion of market value for newly public US biotechs (Image: Genomics Law Report).
ALPN-202 combines dual checkpoint blockade action with T-cell costimulation
| Last Price 23.41 | Change $ -1.31 | Change % -5.30 | Tick N/A |
| Bid N/A | Bid Size 0.00 | Ask 25.70 | Ask Size 3,400.00 |
| Open 24.71 | High 24.95 | Low 23.30 | Prev Close 24.72 |
| Last Trade | Volume 769,831 | 52 Wk Hi 33.80 | 52 Wk Low 23.30 |
| Market Cap 2.9 bi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 121,902,101.00 | EPS (TTM) -6.95 | PE Ratio N/A | Exchange NGS |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 14 | 14 |
| Number of Buys | 14 | 14 |
| Number of Sells | 0 | 0 |
| Net Activity | 31051496 | 31051496 |
| Last 10 Buys | Shares |
|---|---|
| Franz Bernard Humer | 1,000 |
| Owen N. Witte | 1,000 |
| David D. Chang | 1,000 |
| Arie S. Belldegrun | 1,000 |
| James G. Coulter | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| N/A | 0 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 31 | |||
| Low Target Price Estimate | 29 | |||
| Mean Target Price Estimate | 30 | |||
| Standard Deviation | 1.41 | |||
| Date of Most Recent Estimate | 11/05/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-10-29 |
| SC 13D | Filing by person(s) reporting owned shares of common stock in a public company >5% | 11 | 2018-10-25 |
| S-8 | Securities offered to employees under employee benefit plans | 91 | 2018-10-24 |
| SC 13D | Filing by person(s) reporting owned shares of common stock in a public company >5% | 9 | 2018-10-22 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-10-17 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-10-17 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-10-17 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-10-17 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-10-17 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-10-17 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 2 | 0 | 0 | 0 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 1 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.67 | 0 | 0 | 0 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait